Holen Sie sich die Stockscreener-App
9.53
1.14%
-0.11
Schlusskurs vom Vortag:
$9.64
Offen:
$9.72
24-Stunden-Volumen:
37,032
Relative Volume:
0.47
Marktkapitalisierung:
$79.03M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-6.42M
KGV:
-0.999
EPS:
-9.54
Netto-Cashflow:
$-7.45M
1W Leistung:
-12.73%
1M Leistung:
-27.69%
6M Leistung:
-50.98%
1J Leistung:
-2.76%
1-Tages-Spanne:
$9.3501
$9.80
1-Wochen-Bereich:
$9.31
$11.44
52-Wochen-Spanne:
$5.85
$26.38
Cervomed Inc Stock (CRVO) Company Profile
Firmenname
Cervomed Inc
Sektor
Branche
Telefon
(617) 744-4400
Adresse
20 PARK PLAZA, BOSTON
Vergleichen Sie CRVO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| CRVO | 9.57 | 79.03M | 0 | -6.42M | -7.45M | -9.54 |
| VRTX | 450.37 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 747.10 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.88 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.29 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.62 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Cervomed Inc Stock (CRVO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-11-17 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2018-03-21 | Eingeleitet | H.C. Wainwright | Buy |
Cervomed Inc Aktie (CRVO) Neueste Nachrichten
CRVO (CervoMed) EV-to-Revenue : (As of Nov. 20, 2024) - GuruFocus.com
CervoMed Inc.'s (NASDAQ:CRVO) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio - Simply Wall St
CervoMed shares coverage initiated with buy rating on DLB drug potential - Investing.com
CervoMed initiated with a Buy at D. Boral Capital - TipRanks
D. Boral Capital Initiates Coverage of CervoMed (CRVO) with Buy Recommendation - MSN
CervoMed Inc. (NASDAQ:CRVO) Sees Large Growth in Short Interest - MarketBeat
CervoMed FY2024 EPS Lowered by Brookline Capital Management - MarketBeat
AWM Investment Company, Inc. Expands Stake in CervoMed Inc - GuruFocus.com
CervoMed appoints Ordonez, Rosch as SVPs - TipRanks
CervoMed bolsters leadership for neurologic drug development By Investing.com - Investing.com Nigeria
CervoMed bolsters leadership for neurologic drug development - Investing.com
CervoMed Announces Key Senior Leadership Appointments - GlobeNewswire
CervoMed Bolsters Leadership Team Ahead of Crucial Lewy Body Dementia Drug Trial | CRVO Stock News - StockTitan
CervoMed Inc. Reports Increased R&D Expenses Amid Ongoing Trials - TipRanks
CervoMed Inc. (CRVO) Quarterly 10-Q Report - Quartz
CervoMed Inc. Announces Executive Appointments - Marketscreener.com
CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - The Manila Times
CervoMed's Q3 Loss Widens to $4.8M Despite $46.7M Cash Reserve; Awaits Key Trial Data | CRVO Stock News - StockTitan
CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup - GlobeNewswire
CervoMed to Participate in Upcoming Investor Conferences - StockTitan
CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD) - The Manila Times
CervoMed Announces Key Takeaways from Oral Presentations at - GlobeNewswire
CervoMed Inc. (NASDAQ:CRVO) Short Interest Up 7.6% in October - MarketBeat
CervoMed (NASDAQ:CRVO) Shares Down 3.1% – Time to Sell? - Defense World
CervoMed (NASDAQ:CRVO) Stock Price Down 3.1%What's Next? - MarketBeat
CervoMed to Present Phase 2b Trial Results - TipRanks
CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference - GlobeNewswire
Insiders of CervoMed Inc. (NASDAQ:CRVO) were rewarded after last week’s 11% gain - Simply Wall St
CRVOCervoMed Inc. Latest Stock News & Market Updates - StockTitan
CervoMed Announces Last Patient Last Visit in Phase 2b - GlobeNewswire
CervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia with Lewy Bodies (DLB) - StockTitan
CervoMed Ends $20 Million Stock Sales Agreement with BTIG - Yahoo Finance
CervoMed ends sales agreement with BTIG By Investing.com - Investing.com South Africa
CervoMed ends sales agreement with BTIG - Investing.com India
CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference - GlobeNewswire
CervoMed Inc. (NASDAQ:CRVO) Short Interest Update - MarketBeat
CervoMed to Deliver Late-Breaking Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD) - The Manila Times
CervoMed to present on neflamapimod as DLB treatment at CTAD - TipRanks
CervoMed to Deliver Late-Breaking Oral Presentations at the - GlobeNewswire
Armistice Capital LLC Sells 94,363 Shares of CervoMed Inc. (NASDAQ:CRVO) - MarketBeat
There is no way Cerence Inc (CRNC) can keep these numbers up - SETE News
Credo Technology Group (NASDAQ:CRDO) Trading Up 3% - MarketBeat
Certara Inc (CERT)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
Closing Figures Unveiled: Cemtrex Inc. (CETX) Drop -3.49, Closes at 0.14 - The Dwinnex
Examining Certara Inc (CERT) more closely is necessary - US Post News
Cerence Inc. (CRNC)’s $40 Million Revenue Guidance Signals Trouble for Investors - Insider Monkey
(CRVO) Technical Pivots with Risk Controls - Stock Traders Daily
CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236 - StockTitan
Holdings of CERo Therapeutics Holdings Inc. (CERO) are aligned with the stars - SETE News
CERo Therapeutics Holdings Inc. (CERO)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
Finanzdaten der Cervomed Inc-Aktie (CRVO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):